The focus of one cohort of KEYNOTE-021 and of KEYNOTE-189 is to investigate the addition of pembrolizumab to platinum-based chemotherapy plus pemetrexed in patients with untreated advanced non-small-cell lung cancer. Prior reports from both trials have demonstrated significant improvements in survival outcomes with use of the PD-1 inhibitor.
KEYNOTE-021 study results from from WCLC 2019
Lead researcher Corey Langer explains that the study found no correlation between tumor mutation burden and response, progression-free survival and overall survival in previously untreated advanced nonsquamous non-small cell lung cancer patients treated with pembrolizumab plus platinum-based chemotherapy.
Two presentations at WCLC 2019 addressed the role of the tumor mutational burden in predicting response to treatment in these trials.
Title: KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC
Presenter: Corey Langer, University of Pennsylvania, Philadelphia, USA
Sunday, September 8: 16:00–16:10 (Abstract OA04.05)
Title: Evaluation of TMB in KEYNOTE-189: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC
Presenter: Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Sunday, September 8: 16:10–16:20 (Abstract OA04.06)